Caution: JavaScript execution is disabled in your browser or for this website. You may not be able to answer all questions in this survey. Please, verify your browser parameters.

Survey on Alzheimer’s disease Biomarkers

Cerebrospinal fluid (CSF) and blood biomarkers are increasingly used in Alzheimer’s disease (AD) research, but there is an active discussion about the procedures to be adopted in the total testing processes. 

To review the current state of the art in the management of the biomarker’s measurements from the European Laboratories in this specific clinical setting, we would like to invite you to take part in the EFLM survey on Alzheimer’s disease Biomarkers.
The aim of this survey is to assess the current adopted procedure and promote activities for their improvement and harmonization.

The survey will be open until 15 October 2025.
It will take approx. 15 minutes to complete the survey.

Your laboratory may receive more than one invitation to participate in the survey but we would kindly ask you to make only one submission per laboratory.

This survey is created by the EFLM Committee "Harmonisation" of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM).

Thank you for your contribution!

Martina Zaninotto
Chair, ELFM C-H

There are 23 questions in this survey.

Privacy policy.

Summary results of this survey shall be published. Data obtained through this survey are solely accessible by the study coordinator. Your responses will be provided to the coordinator in an anonymized form so that responses and participants cannot be connected as described above.

Your IP-Address will NOT be logged. We will use Cookies, so that you will be able to move back and forward while completing this survey.
To proceed with the survey, please, agree to these conditions.

 
Close